Eli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease in a clinical trial, and is now on course to be the first to have a chronic ...

Eli Lilly and Boehringer Ingelheim's blockbuster diabetes drug Jardiance (empagliflozin) has been granted approval by the US Food and Drug Administration (FDA) for a wider range of heart failure ...

Compared with empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), dapagliflozin produced a similar impact on MI/stroke risk but was associated with an increased risk of heart failure (HF) ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over year.

In pigs receiving anthracyclines, the researchers administered a 20 mg daily dose of the SGLT2 inhibitor empagliflozin, sold ...

Merck), empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), and insulin aspart (Fiasp and NovoLog; Novo Nordisk). Similarly, total spending for all 10 drugs increased from $3.5 to $27.5 billion ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

and empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), respectively. These trials also showed benefit in preventing the progression of CKD or major adverse renal events, but residual risks ...